Pep2Dia® Gummies
Maintaining normal blood glucose levels
Offer a gummy formula combining Pep2Dia®, guarana and chromium, designed to meet the demands of the dietary supplements market in relation to blood sugar balance. A private-label formula in gummy form with an apple flavour, to be taken once daily one gummy in the morning and one in the evening.
Formula
| Ingredients | For 2 gummies | RI* |
|---|---|---|
| Pep2Dia® milk protein hydrolysate | 1400 mg | - |
| Guarana seed extract | 36 mg | - |
| equivalent to dried plant | 180 mg | - |
| Chrome | 40 μg | 100 % |
Claims
- Chromium helps maintain normal blood glucose levels and supports the normal metabolism of macronutrients.
Features
| Flavor | Apple |
| Size | 3g ou 6g |
| Finish | Oiled |
| Shelf life | 24 months |
| Packaging | Bottles, doypacks, samples sachets |
Properties
Pep2Dia® & Chrome & Guarana Apple Gummies - Metabolic Balance & Weight Management
Expand your range of dietary supplements with these gummies combining Pep2Dia®, chromium and guarana, a formula designed for the metabolic balance segment. Each gummy provides 700 mg of Pep2Dia® and 40 µg of chromium, representing 100 per cent of the reference intake for chromium.
The formula combines Pep2Dia® milk protein hydrolysate with chromium picolinate.
Guarana rounds out this blend as an ingredient commonly found in formulations designed for weight loss and weight management.
Available in apple-flavoured gummies, the product is taken at a rate of two gummies per day and is supplied in a jar of 60 gummies. A private-label solution enabling laboratories and brands to expand their range with a formula focused on blood sugar balance and metabolism.
Pep2Dia® Clinical Studies
Pep2Dia® is a whey protein hydrolysate of dairy origin, developed from French milk. In particular, it contains a bioactive dipeptide, alanine-proline (AP), which has been studied for its effect on alpha-glucosidase, a digestive enzyme involved in the conversion of carbohydrates into glucose.
Its benefits are supported by several clinical studies conducted in subjects with high blood glucose levels or prediabetes. In particular, a randomised, double-blind, placebo-controlled study evaluated doses of 700 mg and 1,400 mg of Pep2Dia® prior to a high-carbohydrate meal, with a significant reduction in postprandial blood glucose levels observed at the dose studied.
A further study also assessed prolonged supplementation with 1,400 mg per day for 6 weeks in prediabetic individuals, showing, in particular, a favourable trend in HbA1c levels.
Pep2Dia® is therefore a distinctive active ingredient for the development of food supplements designed to support blood glucose balance and targeted nutritional formulations, with a positioning based on a patented and scientifically validated dairy ingredient.
Source: Postprandial Effects of a Proprietary Milk Protein Hydrolysate Containing Bioactive Peptides in Prediabetic Subjects, Nutrients, 2019.
ClinicalTrials.gov, NCT04375449 – Investigation of Milk Peptides (Pep2Dia®) on Postprandial Blood Glucose Profile in Prediabetic Subjects.
ClinicalTrials.gov, NCT05391854 – Étude clinique visant à évaluer l'effet à long terme de Pep2Dia® sur l'homéostasie glycémique chez des sujets prédiabétiques.
